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Objectives This study examined the mid-term hemodynamic and clinical impact of prosthesis–patient mismatch (PPM) in
patients undergoing transcatheter aortic valve implantation (TAVI) with balloon-expandable valves.
Background PPM can be observed after aortic valve surgery. However, little is known about the incidence of PPM in patients
undergoing TAVI.
Methods Echocardiography and clinical assessment were performed in 165 patients at baseline, before hospital dis-
charge, and at 6 months after TAVI. PPM was defined as an indexed effective orifice area 0.85 cm2/m2.
Results Thirty patients (18.2%) showed PPM before hospital discharge. At baseline, patients with PPM had a larger body
surface area (1.84  0.18 m2 vs. 1.73  0.18 m2, p  0.003) and a greater severity of aortic stenosis (indexed
valve area 0.35  0.09 cm2/m2 vs. 0.40  0.10 cm2/m2, p  0.005) than patients without PPM. Patients with
PPM demonstrated a slower and smaller reduction in mean transaortic gradient, limited left ventricular (LV)
mass regression, and left atrial volume reduction over 6 months compared with patients without PPM. LV filling
pressure, measured by E/e=, tended to remain elevated in patients with PPM. Importantly, a higher proportion of
patients with PPM did not improve in New York Heart Association functional class compared with patients with-
out PPM (36.7% vs. 1.5%, p  0.001), although major adverse valve-related and cardiovascular events did not
differ between the 2 groups.
Conclusions PPM may be observed after TAVI and when present may be accompanied by less favorable changes in trans-
valvular hemodynamics, limited LV mass regression, persistent elevated LV filling pressure, and less improve-
ment in clinical functional status. (J Am Coll Cardiol 2011;58:1910–8) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.027Prosthesis–patient mismatch (PPM) can be observed after
surgical aortic valve replacement for severe aortic stenosis
(AS) (1–4) when the effective orifice area (EOA) of a
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accepted August 2, 2011.normally functioning prosthesis is too small in relation to
the patient’s body size (5). The presence of significant PPM
after aortic valve surgery has been associated with worse
transvalvular hemodynamics and limited regression of left
ventricular (LV) hypertrophy as a result of increased LV
afterload (6). In addition, reduced indexed EOA has been
reported to negatively affect clinical outcomes (1–4).
See page 1919
So far, only a few small series (7–9) have described the
incidence of PPM after transcatheter aortic valve implan-
tation (TAVI), and little is known about its impact on
LV performance and clinical outcomes in these patients.
Therefore, we aimed to evaluate the mid-term hemody-
namic and clinical impact of PPM in patients with severe
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wards SAPIEN bioprosthesis (Edwards Lifesciences, Inc.,
Irvine, California).
Methods
Patient population. A total of 190 consecutive patients
with symptomatic severe AS who underwent TAVI at
Leiden University Medical Center, Leiden, the Nether-
lands, and Centro Cardiologico Monzino, IRCCS, Milan,
Italy, were included. Based on a multidisciplinary team
assessment, all patients had severe AS, defined as an aortic
valve area 1 cm2 or 0.6 cm2/m2, and were considered at
igh operative risk or had contraindications to conventional
ortic valve surgery. Patients with previous aortic or mitral
rostheses, unsuccessful TAVI, or an echocardiographic
ollow-up 6 months were excluded from the present
nalysis.
According to the institutional protocols, all patients
nderwent clinical and echocardiographic evaluation at
aseline, post-procedure (before hospital discharge), and at
months follow-up. The incidence of PPM and the
emodynamic and clinical impact of the presence of PPM
uring follow-up were assessed. Clinical and echocardio-
raphic data were prospectively recorded and retrospectively
nalyzed.
AVI procedure. The balloon-expandable Edwards-
APIEN prostheses (Edwards Lifesciences, Inc.) of either
3 or 26 mm was used in all patients when the aortic
nnulus was 18 to 22 mm and 21 to 25 mm (as confirmed
y transesophageal echocardiography), respectively (10).
his valve consists of a trileaflet bovine pericardial tissue
alve, mounted within a stainless steel balloon-expandable
tent. As previously described (11), the device was delivered
ia either a transfemoral (retrograde) or transapical (ante-
rade) approach. The transapical approach was performed
n patients with unsuitable aortoiliofemoral anatomy such as
liofemoral arteries7 to 8 mm, marked tortuosity, abdom-
nal aortic aneurysm, porcelain aorta, and/or previous aor-
oiliac surgery or intervention (12). All procedures were
erformed under transesophageal echocardiographic and
uoroscopic guidance.
ransthoracic echocardiography. Transthoracic echocar-
iography was performed in all patients at baseline, before
ospital discharge, and at 6-month follow-up, using a
ommercially available ultrasound system (Vivid-7, General
lectric, Horten, Norway). All images were digitally stored for
ffline analysis (EchoPAC version 108.1.5, GE-Vingmed,
orten, Norway) and included standard 2-dimensional, color,
ulsed, and continuous-wave Doppler acquisitions (13–15).
tandard linear LV dimensions were obtained (14), and LV
ass was calculated as recommended (14). LV end-diastolic
nd -systolic volumes were measured from the standard apical
iews according to the biplane Simpson method (14) and
ndexed to body surface area (BSA). Next, LV ejection fraction
as derived. Similarly, maximal left atrial (LA) volumes wereeasured using the biplane Simp-
on method and indexed to BSA
14). Pulmonary artery systolic
ressure was estimated from the
oppler spectral signal of tricuspid
egurgitation jet (16). The pres-
nce of aortic or mitral regurgita-
ion was evaluated using color
oppler, and the severity was as-
essed according to current guide-
ines (15).
To assess LV diastolic func-
ion, transmitral early (E-wave)
nd late (A-wave) velocities and
-wave deceleration time were
easured using pulsed-wave
oppler at the mitral leaflet tips
16). Pulmonary venous flow ve-
ocities during systole and dias-
ole were also recorded (16). By
ntegrating transmitral and pul-
onary venous flow analysis, diastolic dysfunction was
lassified as follows: 1) impaired relaxation if mitral E/A
0.8 and pulmonary venous systolic velocity  diastolic
elocity; 2) pseudonormal filling if mitral E/A  0.8 to 1.5,
E-wave deceleration time  160 to 200 ms and pulmonary
venous systolic velocity  diastolic velocity; and 3) restric-
tive filling if E/A 2, E-wave deceleration time 160 ms,
and pulmonary venous systolic velocity  diastolic velocity
(16). In addition, peak early diastolic velocities of the septal
mitral annulus (e=) were measured by pulsed wave tissue
Doppler imaging from the apical 4-chamber view (16).
Then, the ratio of E/e= was calculated. In patients who were
not in sinus rhythm, e= was used as an additional parameter
to help determine the degree of LV diastolic dysfunction:
impaired relaxation if e=10, pseudonormal filling if e=8,
and restrictive filling if e= 5 (17).
The aortic annulus was measured in a zoomed-up para-
sternal long-axis view as recommended (14). Similarly, the
left ventricular outflow tract (LVOT) diameter was mea-
sured within 5 to 10 mm into the LVOT from the level of
the aortic annulus in mid-systole (13). Pulsed-wave Doppler
was used for LVOT measurements and continuous-wave
Doppler was used for transaortic measurements. Using the
continuity equation (13), the aortic valve area was obtained
and indexed to BSA. In patients with sinus rhythm, the 3
best available signals were recorded and averaged. In pa-
tients who were not in sinus rhythm, a minimum of 5
measurements was averaged (13).
Definition of PPM after TAVI. After TAVI, the EOA of
the prosthesis was similarly calculated using the continuity
equation approach. From the parasternal long-axis view in a
zoomed mid-systolic frame, the LVOT was measured just
below the ventricular end of the prosthesis (but not inside it)
to avoid the area of subvalvular flow acceleration. The EOA
Abbreviations
and Acronyms
AS  aortic stenosis
BSA  body surface area
EOA  effective orifice
area
LA  left atrium
LV  left ventricular
LVOT  left ventricular
outflow tract
MAVCE  major adverse
valve-related and
cardiovascular event(s)
NYHA  New York Heart
Association
PPM  prosthesis–patient
mismatch
TAVI  transcatheter aortic
valve implantationwas subsequently calculated, assuming a circular geometry
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Prosthesis–Patient Mismatch and TAVI October 25, 2011:1910–8of the LVOT, and indexed to BSA. PPM was defined as an
indexed EOA 0.85 cm2/m2 (3,6).
Follow-up data collection. Before hospital discharge and
at 6-month follow-up, clinical evaluation included the
classification of heart failure symptoms according to the
New York Heart Association (NYHA) functional class.
In addition, all adverse procedural and in-hospital events
and mortality were recorded. In particular, major adverse
valve-related events, defined as any structural deteriora-
tion or nonstructural prosthesis dysfunction, valve throm-
bosis, embolism, bleeding event, or valve endocarditis,
were recorded (18).
During follow-up, major cardiovascular events, such as
death, myocardial infarction, stroke, and heart failure, were
recorded. A combined endpoint of major adverse valve-
related and cardiovascular events (MAVCE) was used for
Kaplan-Meier survival analysis.
Statistical analysis. Continuous variables are presented as
mean and SD unless otherwise specified. Categorical vari-
ables are presented as frequencies and percentages. Pre-
procedural and follow-up data were compared between
patients with PPM (indexed EOA 0.85 cm2/m2) and
without PPM (indexed EOA 0.85 cm2/m2). An unpaired
Student t test or chi-square test or the Fisher exact test was
sed to compare continuous or categorical variables, as
ppropriate. A chi-square test was used to compare cate-
orical variables when no cells had an expected count 5,
hereas the Fisher exact test was performed when 1 cell
ad an expected count 5. A 2-way repeated-measures
nalysis of variance was used to evaluate the effects of time
baseline vs. hospital discharge vs. 6-months follow-up) and
he presence or absence of PPM on each echocardiographic
ariable (EOA, transaortic gradient, LV ejection fraction
nd mass, LA volume, and E/e=), followed by post hoc
nalyses for significant results performed using Bonferroni
orrection with 3 pairwise comparisons. In addition, the
nteraction between group (presence or absence of PPM)
nd time was also analyzed for each echocardiographic
ariable and expressed as group-by-time analysis of variance.
inally, the MAVCE-free survival rates were presented as
aplan-Meier curves, and the log-rank test was used for
omparison between groups. A 2-tailed probability value of
0.05 was considered statistically significant. All statistical
nalyses were conducted using SPSS for Windows version
6 (SPSS Inc., Chicago, Illinois).
esults
atient population. A total of 190 patients were initially
ncluded. Of these patients, 25 patients were excluded for
ifferent reasons. Eight patients were excluded due to previous
ortic or mitral prostheses, and 4 patients did not have a
uccessful implantation procedure. Nine patients died before 6
onths and were subsequently excluded from further analysis.
hese events were due to in-hospital deaths from massivetroke (n  1), pulmonary disease (n  2), heart failure (n ), and deaths within 6 months from end-stage lung disease
n  1), chronic renal disease (n  1), and myocardial
nfarction (n  1). They were unrelated to PPM as none of
hese patients demonstrated PPM post-TAVI. In addition, a
urther 4 patients were excluded due to extremely poor acoustic
indows and echocardiographic images unsuitable for accurate
nterpretation. Therefore, a total of 165 patients composed the
nal study population.
The incidence of PPM (indexed EOA 0.85 cm2/m2)
post-TAVI was 18.2% (n  30), as assessed by transthoracic
echocardiography before hospital discharge. Baseline clinical
and echocardiographic characteristics of patients with and
without PPM are summarized in Tables 1 and 2. Patients with
PPM had a significantly larger BSA (Table 1) (19). In
addition, patients with PPM had a greater severity of AS at
baseline (indexed aortic valve area 0.35 0.09 cm2/m2 vs. 0.40
 0.10 cm2/m2, p  0.005) compared with patients without
PPM, although the calculated valve areas were not significantly
different. There was also a trend toward a smaller LVOT,
sinotubular junction, and ascending aorta in patients with
PPM. However, the aortic annulus diameter, on which the
prosthesis sizing was based, did not differ between the 2 groups
(Table 2).
Hemodynamic impact of PPM assessed by echocardiography.
Echocardiographic Doppler data at baseline, hospital dis-
charge, and 6-month follow-up are summarized in Figure 1.
Per the definition, patients with PPM were characterized by
a smaller EOA at discharge and 6-month follow-up com-
pared with those without PPM (Fig. 1A). Accordingly,
patients with PPM demonstrated a slower and smaller
reduction in mean transaortic gradient post-TAVI, result-
ing in a higher transvalvular gradient at 6-month follow-up
(16  8 mm Hg vs. 10  4 mm Hg, p  0.001) compared
with patients without PPM (Fig. 1B).
Small improvements in LV ejection fraction were noted in
both groups of patients with and without PPM post-TAVI,
and no significant difference in LV ejection fraction was
observed between the 2 groups (Fig. 2A). However, in terms of
LV mass regression, patients with PPM had a smaller LV mass
regression 6 months post-procedure (with a reduction in LV
mass index of 7.2  4.6% vs. 21.1  10.6%, p  0.001)
ompared with patients without PPM (Fig. 2B). Similarly,
atients with PPM had a smaller reduction in LA volume 6
onths post-TAVI (with a reduction in LA volume index of
8.0  9.7% vs. 26.0  10.5%, p  0.001) compared with
atients without PPM (Fig. 2C).
With regard to LV filling pressure, E/e= remained elevated
n patients with PPM at 6 months despite TAVI (Fig. 2D). In
ontrast, TAVI resulted in the significant reduction of LV
lling pressure in patients without PPM (with a reduction
n E/e= of 29.7  7.0% vs. 4.6  21.4%, p  0.001)
(Fig. 2D). When LV diastolic function was analyzed ac-
cording to diastolic dysfunction grade, a higher proportion
of patients without PPM showed improvement in LV
diastolic function than those with PPM (47.4% vs. 10%,
p  0.001) (Fig. 3A).
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October 25, 2011:1910–8 Prosthesis–Patient Mismatch and TAVIIn terms of aortic regurgitation, there was no difference in
the proportion of patients with aortic regurgitation grade
2 before hospital discharge (13.3% vs. 23.0%, p  0.33)
nd at 6-month follow-up (13.3% vs. 28.1%, p  0.11) in
the group with and without PPM. During 6-month follow-
up, the presence of PPM did not have a significant effect on
aortic regurgitation post-TAVI. The proportion of patients
who did (33.3% vs. 29.6%) or did not improve (66.7% vs.
70.4%, p  0.83) in terms of aortic regurgitation grade
as similar in patients with and without PPM. Similarly,
itral regurgitation was not affected by the presence of
PM. Patients with PPM who did (26.7% vs. 25.2%) or
id not improve (73.3% vs. 74.8%, p  0.82) in terms of
itral regurgitation grade was similar to the group
ithout PPM.
linical impact of PPM. The majority of patients (n 
52, 92.1%) reported a significant improvement in
YHA functional class at 6 months after TAVI. How-
ver, there was a significant proportion of patients with
PM (n  11, 36.7%) who did not demonstrate an
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Age, yrs
Male
Body surface area, m2
Body mass index, kg/m2
Logistic EuroSCORE
NYHA functional class
II
III
IV
Previous myocardial infarction
Previous coronary bypass surgery
Previous percutaneous coronary intervention
Peripheral vascular disease
Hypertension
Hypercholesterolemia
Diabetes
Smoking
Frailty‡
Heart rhythm
Sinus
Atrial fibrillation
Pacemaker
Creatinine clearance, ml/min
Hemoglobin, g/dl
Approach
Transfemoral
Transapical
Prosthesis size, mm
23
26
Values are mean SD or %. *p value for comparison between PPM an
test. ‡Frailty assessed according to Fried et al. (19).
NYHA  New York Heart Association; PPM  prosthesis–patient mmprovement in functional class status. In contrast, Tmong patients without PPM post-TAVI, only a small
inority of patients (n  2, 1.5%) did not show an
mprovement in functional status (Fig. 3B).
No patients were lost during the follow-up period (mean
7.6  7.0 months) and a total of 18 MAVCE were
bserved. Three events (10%) occurred in the group with
PM: end-stage lung disease, bleeding event, and infective
ndocarditis. The remaining 15 events (11.1%) occurred in
atients without PPM: 2 deaths (liver cirrhosis, intestinal
schemia), myocardial infarction (n  3), stroke (n  2),
eart failure (n  5), and bleeding events (n  3).
mportantly, there was no significant difference between
atients with and without PPM in terms of MAVCE
log-rank p  0.82) (Fig. 4).
iscussion
he present evaluation demonstrated that PPM is rather
ommon and occurred in 18.2% of patients undergoing
M
30)
No PPM
(n  135) p Value*
9.8 81.1 6.2 0.084
.7 39.3 0.84
0.18 1.73 0.18 0.003
4.0 25.5 5.1 0.25
9.9 21.9 12.3 0.91
.3 17.0 0.46†
.7 68.2
.0 14.8
.7 16.3 1.00
.3 18.5 0.80
.0 22.2 0.13
.7 28.9 0.82
.0 75.5 0.62
.3 36.3 0.67
.3 17.0 0.080
.0 31.1 0.18
.7 21.5 0.81
.0 81.5 0.80
.0 14.8 0.77†
.0 3.7 0.16†
6.0 49.3 21.3 0.57
2.5 11.6 2.1 0.53
.3 46.7 0.11
.7 53.3
.0 35.6 0.15
.0 64.4
M using an unpaired t test or chi-square test. †p value by Fisher exact
.PP
(n 
77.8
36
1.84
26.6
22.2
23
56
20
16
23
10
26
70
43
33
20
26
80
10
10
46.8
11.3
63
36
50
50
d no PPAVI with balloon-expandable valves. In particular, pa-
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Prosthesis–Patient Mismatch and TAVI October 25, 2011:1910–8tients with PPM were accompanied by less favorable
changes post-TAVI compared with patients without PPM,
with higher transvalvular gradient, limited LV mass regres-
sion, and LA volume reduction, and with persistent elevated
LV filling pressures. Finally, more patients reported a lack
of clinical improvement in the group with PPM, although
the MAVCE-free survival did not differ between the 2
groups.
Incidence of PPM in patients undergoing TAVI. To
minimize paravalvular regurgitation and to ensure adequate
annular sealing, it is generally recommended that the
implanted prosthesis be slightly larger than the native aortic
annulus for the currently applied percutaneous systems (20).
For example, in the balloon-expandable delivery system of
the Edwards SAPIEN valves, the 23-mm valve is used for
aortic annulus between 18 and 22 mm, whereas the 26-mm
valve is used for aortic annulus between 21 and 25 mm
Baseline Echocardiographic CharacteristicsTable 2 Baseline Echocardiographic Charac
Aortic valve area, cm2
Aortic valve area index, cm2/m2
Left ventricular outflow tract, cm
Aortic annulus, cm
Aortic sinus, cm
Sinotubular junction, cm
Ascending aorta, cm
Mean transaortic gradient, mm Hg
Left ventricular end-diastolic volume index, ml/m2
Left ventricular end-systolic volume index, ml/m2
Left ventricular ejection fraction, %
Left ventricular mass index, g/m2
Left atrial volume index, ml/m2
E-wave, cm/s
A-wave, cm/s
Mitral E/A ratio
Mitral deceleration time, ms
E=, cm/s
E/e=
Diastolic function
Impaired relaxation
Pseudonormal filling
Restrictive filling
Pulmonary artery systolic pressure, mm Hg
Aortic regurgitation grade
0
I
II
III
Mitral regurgitation grade
0
I
II
III
Values aremean SD or %. *p value for comparison between PPM and
PPM  prosthesis–patient mismatch.(10,21). Despite these indications, the current study rshowed that PPM developed before hospital discharge in
18.2% of patients who underwent Edwards SAPIEN
valve implantation.
Using the definition of an indexed EOA 0.85 cm2/m2,
he incidence of PPM post-TAVI has been reported to be
igher (32% to 39%) in patients who underwent CoreValve
mplantation (8,9). This difference can be partially explained
y the fact that only 1 size of the device (26 mm, the
mallest) was available at the time of TAVI in one-fourth of
he patients (27%) in the reported series (9). In addition, the
ifferences in prosthesis design may play a role. The Edwards
APIEN valve is a trileaflet valve mounted on a balloon-
xpandable stainless stent frame that is 14.5 mm or 16 mm
n height (for the 23- or 26-mm valve, respectively) and is
mplanted intra-annularly (21). Conversely, the CoreValve
designed for supra-annular implantation) has a longer
rame of 53 or 55 mm (for the 26- or 29-mm device,
ics
PPM
(n  30)
No PPM
(n  135) p Value*
64 0.16 0.69 0.17 0.096
35 0.09 0.40 0.10 0.005
.8 2.1 20.4 1.9 0.065
.2 2.1 21.9 2.2 0.15
.7 4.7 32.7 4.1 0.99
.0 4.0 27.5 4.2 0.067
.0 4.8 33.0 4.2 0.062
44 18 49 17 0.081
68 31 61 20 0.23
32 28 27 16 0.13
52 16 55 11 0.30
49 50 151 38 0.84
48 11 52 15 0.095
92 24 92 29 0.96
96 44 100 33 0.64
20 0.78 1.02 0.61 0.20
19 82 222 77 0.86
.4 0.9 4.7 1.1 0.19
.2 8.3 20.6 7.1 0.28
30.0 43.0 0.38†
53.3 45.9
16.7 11.1
45 7 42 9 0.100
20.0 19.3 0.63†
50.0 58.5
26.7 15.6
3.3 6.7
20.0 13.3 0.57†
56.7 53.3
16.7 27.4
6.7 5.9
using unpaired t test or chi-square test. †p value by Fisher exact test.terist
0.
0.
19
21
32
26
32
1
1.
2
4
22espectively), with the lower third sitting within the LVOT
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October 25, 2011:1910–8 Prosthesis–Patient Mismatch and TAVI(21). These differences may account for a potentially higher
incidence of PPM with the CoreValve prosthesis. Finally,
optimal prosthesis positioning may be important for good
expansion and functioning of the transcatheter aortic bio-
prosthesis. Recently, Jilaihawi et al. (8) reported that a lower
incidence of PPM could be achieved with optimal position-
ing of the prosthesis compared with suboptimal positioning
(16% vs. 48%, p  0.015) in 50 patients who underwent
CoreValve implantation.
Of interest, the incidence of PPM has been reported to be
lower with the balloon-expandable transcatheter valve com-
pared with surgical bioprosthesis. In a recent matched study
of 50 patients who underwent TAVI with an Edwards
SAPIEN valve and 2 other groups of 50 patients who
underwent surgery with a stented or a stentless bioprosthesis
valve (7), the incidence of severe PPM (defined as an
indexed EOA 0.65 cm2/m2) was significantly higher in
patients with either a stented (26%) or a stentless (28%)
bioprosthetic valve than in patients who underwent TAVI
(11%). Our findings extended this to a larger population
of patients who underwent Edwards SAPIEN valve
implantation. The lower incidence of PPM in the TAVI
series compared with the surgical series may be partly
explained by the absence of a sewing ring and a thinner
transcatheter stent frame. Furthermore, sizes of surgical
prostheses are generally smaller than transcatheter pros-
theses, although this might be offset by a routine annular
debridement and removal of the native valve before
implantation during surgery, which cannot be performed
during TAVI (7).
The current study showed that patients with a larger BSA
Figure 1 Impact of PPM on Transvalvular Hemodynamics
Comparison of changes in aortic effective orifice area index (A) and mean transao
The p value is for the group-by-time analysis of variance. Error bars denote the SE
below each graph. *p  0.05 between PPM and no PPM. Bonferroni post-hoc teswere more prone to the development of PPM post-TAVI. tThis is probably due to a higher transvalvular flow along
with a higher cardiac output required in patients with a
larger BSA. Similar findings were observed in the cited
study of Jilaihawi et al. (8), including 50 patients who
underwent TAVI with a CoreValve prosthesis, in which a
larger BSA was observed in patients with PPM compared
with patients without PPM (1.8  0.3 vs. 1.7  0.2). It is
mportant to highlight that currently the choice of trans-
atheter bioprosthesis size depends exclusively on the aortic
alve annulus, which was not different between the 2 groups
f patients in the present study. These observations suggest
hat the limited transcatheter prosthesis sizes currently
vailable (for either system) are probably inadequate to avoid
PM, especially in a subset of patients with a larger BSA
nd taking into account that additional maneuvers, such as
emoval of the calcified native valve before implantation and
oot enlargement, cannot be performed. To avoid PPM, a
arger selection of transcatheter valve sizes (taking BSA into
onsideration) and continued improvement of valve design
ith a better hemodynamic profile (to provide a larger
ross-sectional area for blood flow) may be necessary.
owever, excessive oversizing of the currently used trans-
atheter prosthesis has to be weighed against the risk of
ortic rupture during balloon expansion, especially in pa-
ients with a calcified aortic root.
emodynamic impact of PPM. In the present study, a
arked reduction in the mean transvalvular gradient was
bserved in all patients post-TAVI, in line with previously
eported TAVI series (11). However, this study highlighted
hat patients with PPM showed less benefit in terms of
ean transvalvular gradient reduction compared with pa-
adient (B) in patients with and without prosthesis–patient mismatch (PPM).
asurement values (mean  SD) at the corresponding time point are given
0.05 versus baseline. ‡p  0.05 versus baseline.rtic gr
M. Me
t: †p ients without PPM. Similar findings have been described
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Prosthesis–Patient Mismatch and TAVI October 25, 2011:1910–8for patients with PPM with a surgical prosthesis who
showed high transvalvular gradient even in the presence of
a normally functioning prosthesis (6).
The impact of small indexed EOA and its residual
high post-operative gradient on the delay of LV mass
regression has been well documented in patients who
underwent aortic valve replacement (22,23). Tasca et al.
(23) showed that the extent of LV mass regression was
related to the extent of the increase in indexed EOA after
aortic valve surgery. Similarly, the current study showed
that LV mass regression post-TAVI was more pro-
nounced in patients without PPM, whereas in patients
with PPM, the regression of LV hypertrophy was less
marked (Fig. 2B). This observation might have important
clinical implications because regression in LV hypertro-
phy has been reported to be an important predictor of
Figure 2 Hemodynamic Impact of PPM
Comparison of changes in left ventricular ejection fraction (A), left ventricular mas
prosthesis–patient mismatch (PPM). Error bars denote the SEM. Measurement va
*p  0.05 between PPM and no PPM. Bonferroni post-hoc test: †p  0.05 versussurvival after aortic valve replacement (24). Whether thisfinding extends to the TAVI population needs to be
determined in future studies. In the current study, pa-
tients with PPM were observed also to exhibit a more
delayed reduction in LA volume and persistently elevated
LV filling pressures at 6 months post-TAVI (Fig. 2)
compared with patients without PPM. These observa-
tions are presumably the result of a combination of
incomplete relief of outflow tract obstruction and of a
residual significant LV hypertrophy. Ikonomidis et al.
(25) previously showed that abnormal LV relaxation was
associated with residual LV hypertrophy in patients with
isolated AS who had undergone aortic valve replacement.
Accordingly, in the present study, only a small proportion
(10%) of patients with PPM had improvement in their
LV diastolic grades despite the relief of severe AS,
whereas more patients without PPM (47%) exhibited a
x (B), left atrial volume index (C), and E/e= (D) in patients with and without
ean  SD) at the corresponding time point are given below each graph.
line. ‡p  0.05 versus baseline. §p  0.05 versus discharge.s inde
lues (m
basesignificant improvement in LV diastolic function.
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present study is that the presence of PPM negatively
affected the improvement in NYHA functional class at 6
months post-TAVI. This is in line with previous studies
that showed that PPM (defined as an indexed EOA 0.85
cm2/m2) was independently associated with limited im-
provement NYHA functional class after aortic valve re-
placement with a stented bioprosthesis (26). In 312 patients
who underwent bioprosthetic aortic valve replacement, Ble-
iziffer et al. (27) also observed that patients without PPM
could achieve a better physical exercise capacity compared
with patients with PPM. The suboptimal improvements in
valvular hemodynamics and the higher residual afterload
post-TAVI in patients with PPM could have contributed to
the lack of clinical improvement. However, a recent study by
Tzikas et al. (9), which included 74 patients who underwent
TAVI with the CoreValve, reported that the functional
status in terms of NYHA functional class did not differ
between patients with (n 12) and without (n 62) severe
Figure 3 Impact of PPM on Left Ventricular
Diastolic Function and Symptoms
Comparison of the proportion of patients with changes in left ventricular dia-
stolic dysfunction grade (A) and New York Heart Association (NYHA) functional
class (B) at 6 months after transcatheter aortic valve implantation in patients
with and without prosthesis–patient mismatch (PPM). p value denotes the com-
parison between patients with and without PPM.PPM. One of the plausible explanations is that this obser-vation was made by comparing the proportion of patients
with NYHA functional class I to II versus III to IV 6
months post-TAVI in the 2 groups (9). Examining the
paired changes in NYHA functional class from baseline to
6 months post-TAVI (Fig. 3B) may provide more reliable
information on the impact of PPM on an individual patient
basis.
So far, there are conflicting reports on the impact of PPM
on clinical outcome after aortic valve replacement
(1,2,4,28,29). Part of the controversy stems from the use of
either the in vitro or the in vivo EOA measurement used to
define PPM (5). Nonetheless, using the indexed EOA as a
parameter to define PPM, recent series (1–4) demonstrated
that patients without significant PPM had better early and
late mortality benefits. In addition, patients without PPM
exhibit more freedom from congestive heart failure after
aortic valve replacement (30). However, the present study
showed that there was no significant difference in terms of
freedom from MAVCE between patients with or without
PPM post-TAVI, which is similar to the finding of a recent
series of TAVI using the CoreValve system (9).
Study limitations. Due to a relatively short follow-up
period and few major adverse events observed in the present
study, the effect of PPM on clinical outcomes will need to be
verified in a larger population with a longer follow-up
period post-TAVI.
Conclusions
In patients with AS who underwent TAVI with balloon-
expandable valves, PPM may be observed. When present,
Figure 4 Kaplan-Meier Curves for Major Adverse Events
After Transcatheter Aortic Valve Implantation
Kaplan-Meier probability of freedom from combined major adverse valve-related
and cardiovascular events (MAVCE) in patients with and without prosthesis–
patient mismatch (PPM).
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Prosthesis–Patient Mismatch and TAVI October 25, 2011:1910–8PPM may be accompanied by less favorable changes in
transvalvular hemodynamics post-TAVI, together with lim-
ited LV mass regression and LA volume reduction and with
persistent elevated LV filling pressure. More importantly,
PPM may be also associated with less functional improve-
ment after TAVI.
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